Angiotensin (1-7) (Synonyms: Asp-Arg-Val-Tyr-Ile-His-Pro ) |
Catalog No.GP10077 |
Ang-(1-7) (H - Asp - Arg - Val - Tyr - Ile - His - Pro - OH)는 내인성 펩타이드 단편으로, Ang I 또는 Ang II를 각각 endo- 또는 carboxy-peptidase를 통해 생산할 수 있습니다[1].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51833-78-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: |
Competition assays using purified canine ACE are determined using a fixed concentration of the substrate Hip-His-Leu (1 mM) and varying the concentrations of the competing agents [Lisinopril (0.1 to 100 nM), Angiotensin (1-7) (10 nM to 10 μM), or Sar1, Thr8-Ang II (10 nM to 10 μM)]. Inhibitory constants (IC50) are determined from the respective competition curves. To study the effect of Angiotensin (1-7) on BK metabolism in intact coronary rings, 125I-[Tyr0]-BK (final concentration of 1 nM) is added to the tubes containing three rings preincubated with 1 mL Krebs' buffer and aerated with 95% O2 and 5% CO2 at 37°C. Lisinopril (2 μM), Angiotensin (1-7) (2 μM), or Krebs' buffer as control are added to the rings 10 minutes before addition of the radiolabeled BK. Aliquots of the incubation medium are removed at 5, 10, and 20 minutes and diluted with 1% HFBA to inhibit peptidase activity[1]. |
Cell experiment: |
500 μM Methylglyoxal is incubated with 100 μM BSA dissolved in phosphate buffered saline (PBS) for 24 hours, then washed on 10 kDa filters to remove excess methyl glyoxal, reconstituted with DMEM/F12 serum free media and passed through a 0.2 μmicron filter. TGF-β (5 ng/mL) is prepared to treat cells in a subset of experiments. Cells are co-treated with one or combinations of the following: Angiotensin (1-7) (100 nM), D-Ala7-Ang-(1-7) (10 μM), ERK1/2 kinase inhibitor, PD 98059 (1 μM), TGF-β receptor kinase inhibitor; SB525334 (1 μM), the AT1 receptor antagonist Losartan (1 μM), the renin inhibitor Aliskerin (1 μM) and the ACE inhibitor Lisinopril (1 μM)[2]. |
Animal experiment: |
Mice[3] Male and female BALB/c mice (1:1 ratio, 6-10 weeks old, mean weight 20 g.) are used. Angiotensin fragment 1-7 acetate salt hydrate (Ang 1-7) is dissolved in 0.9% saline (vehicle) at 1 mg/mL and stored at -80°C. Various doses (0.01, 0.06, 0.1, 0.3 and 1 mg/kg) are freshly prepared from the stock each day of the experiment, and administered to mice by daily intra-peritoneal (i.p) injections in a volume of 500 μL per injection, either before (prophylactic approach) or after (treatment approach) DSS treatment. A779 (MAS-1 R antagonist) is similarly dissolved in distilled water at 1 mg/mL and stored at -80°C. A freshly prepared dose of 1 mg/kg is administered to a second group of mice by daily i.p injections in a volume of 500 μL daily (for 4 days) along with colitis induction (prophylactic approach). A third group of mice receive DSS containing water and daily i.p injections of 0.9% saline (vehicle). The fourth group receive DSS containing water along with daily i.p injections with Dexamethasone (DEX) at doses of 0.01-1.0 mg/kg or its vehicle (0.9% saline) (prophylactic approach). Rats[4] Twenty six ovariectomized female Wistar rats weighing 200±20 g are used. Angiotensin (1-7) is administered intravenously by a microsyringe pump at two different continuous doses of 100 and 300 ng/kg/min after antagonist/saline infusion. Each dose is infused for 15 min; and MAP, RPP, and RBF are recorded during Angiotensin (1-7) infusion and the last 3-5 min of each dose measured as “response to Angiotensin (1-7) infusion”. During Angiotensin (1-7) infusion, RPP is sustained at pre-Ang1-7 infusion levels via an adjustable aortic clamp. At the end of the experiment, the rats are humanely killed by anesthetic overdose, and the left kidneys are removed and weighed immediately. |
References: [1]. Vaz-Silva J, et al. The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium. Reprod Sci. 2009 Mar;16(3):247-56. |
Ang-(1-7) (H - Asp - Arg - Val - Tyr - Ile - His - Pro - OH)는 내인성 펩타이드 단편으로, Ang I 또는 Ang II를 각각 endo- 또는 carboxy-peptidase를 통해 생산할 수 있습니다[1].
Ang-(1-7)은 Ang II와 같이 다양한 장기 및 조직에서 광범위한 효과를 나타내며, 초기에 기술된 심혈관계 및 신장 작용을 초과합니다. 이러한 효과는 Mas에 의해 매개되며, Ang II의 대부분의 유해한 영향을 상쇄할 수 있습니다. 상호작용인 Ang-(1-7)/Mas는 PI3K (인산화 인수화효소 3-키나아제)/AKT 및 ERK (세포외신호조절단백질) 경로와 NO, FOXO1 (forkhead box O1), COX-2(cyclo-oxygenase-2)와 같은 하류 효소를 포함하는 다양한 신호전달 경로를 규제합니다. 이러한 메커니즘을 통해 Ang-(1-7)은 폐, 간 및 신장과 같은 장기에서 섬유화 및 염증 등의 병리학적 조건을 개선할 수 있습니다.[2]
또한, 이 헵타펩타이드는 대사에 긍정적인 영향을 미치며, 포도당 흡수와 지질분해를 증가시키고 인슐린 저항성과 이상지질혈증을 감소시킵니다. Ang-(1-7)은 학습 및 기억에 대한 영향 외에도 허혈성 뇌졸중에 대한 뇌보호 기능을 개선할 수 있습니다. 생식계도 Ang-(1-7) 치료로 영향을 받아 난자 발생, 정액 생성 및 성 스테로이드 합성이 증대될 수 있습니다. 마지막으로, Ang-(1-7)은 세포 증식 억제 및 혈관 신생 억제 능력 때문에 잠재적인 항암 치료제로 간주됩니다.[2]
References:
1. Santos et al (2000) Angiotensin-(1-7): an update. Regul.Pept. 91 45.
2. Danielle G. P., Thiago V., Robson A. S. Angiotensin-(1-7): beyond the cardio-renal actions. Clinical Science (2013) 124, (443–456)
Cas No. | 51833-78-4 | SDF | |
Synonyms | Asp-Arg-Val-Tyr-Ile-His-Pro | ||
Chemical Name | Angiotensin (1-7) | ||
Canonical SMILES | CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N | ||
Formula | C41H62N12O11 | M.Wt | 899 |
Solubility | ≥89.9mg/mL in DMSO | Storage | Desiccate at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.1123 mL | 5.5617 mL | 11.1235 mL |
5 mM | 0.2225 mL | 1.1123 mL | 2.2247 mL |
10 mM | 0.1112 mL | 0.5562 mL | 1.1123 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *